Key result
Supplemental oxygen therapy has no positive or negative effects on cardiovascular functions, mortality, morbidity, or pain in normoxic patients with STEMI and should be omitted.
Why the study?
Does supplemental oxygen therapy improve cardiovascular functions, mortality, morbidity, or pain in normoxic patients with STEMI?
Does supplemental oxygen therapy improve cardiovascular functions, mortality, morbidity, or pain in normoxic patients with STEMI?
Routine supplemental oxygen therapy provides no clinical benefit in normoxic STEMI patients and should be omitted from standard care.
Supplemental oxygen (O2) therapy in patients with chest pain has been a cornerstone in the treatment of suspected myocardial infarction (MI). Recent randomized controlled trials have, however, shown that supplemental O2 therapy has no positive nor negative effects on cardiovascular functions, mortality, morbidity or pain in normoxic patients with suspected MI and foremost patients with ST Elevation Myocardial Infarction (STEMI). O2 therapy in normoxic STEMI patients should therefore be omitted. More studies are needed in discussing hemodynamically unstable STEMI patients, as well as patients with non-STEMI, unstable angina and other emergency conditions.
No takes yet. Share an insight, caveat, or question.
Ardavan Khoshnood (2018) conducted an editorial in ST Elevation Myocardial Infarction (STEMI). Supplemental oxygen therapy vs. Ambient air was evaluated. Supplemental oxygen therapy has no positive or negative effects on cardiovascular functions, mortality, morbidity, or pain in normoxic patients with STEMI and should be omitted.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: